MetacavirAlternative Names: PNA
Latest Information Update: 25 Nov 2016
At a glance
- Originator Nanjing Chang'ao Pharmaceutical
- Developer Guangzhou Yipinhong Pharmaceutical; Nanjing Chang'ao Pharmaceutical
- Class Antivirals
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-B in China (PO, Capsule)